Results 21 to 30 of about 21,298 (206)

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome

Cancer Research, Statistics, and Treatment, 2020
Background: Fulvestrant has been shown to improve survival in hormone-positive, HER2-negative advanced breast cancer (ABC). There is no study on fulvestrant from India.
Indhuja Muthiah Vaikundaraja, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Jayachandran Perumal Kalaiarasi, Nikita Mehra, Arun Kumar Rajan, Gangothri Selvarajan, Siva Sree Kesana, Balasubramanian Ananthi, Priya Iyer, Geetha Senguttuvan, Manjula Rao, Arvind Krishnamurthy, Sridevi Velusamy, Hemanth Raj, Rama Ranganathan, Shirley Sundersingh, Selvaluxmy Ganesarajah, Trivadi S Ganesan, Tenali Gnana Sagar   +19 more
doaj   +1 more source

Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017 [PDF]

, 2017
The most common endocrinopathy associated with McCune-Albright Syndrome (MAS) is peripheral precocious puberty (PP) which occurs far more often in girls than in boys.
Eugster, Erica A., Neyman, Anna
core   +1 more source

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. [PDF]

, 2017
Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a CDK4/6i-based trial, as first-line therapy in metastatic breast cancer ...
Abouharb, Sausan, Bashour, Sami I, Brown, Powel H, Doostan, Iman, Ibrahim, Nuhad K, Karuturi, Meghan, Keyomarsi, Khandan, Koenig, Kimberly B, Litton, Jennifer K, Moulder-Thompson, Stacy L, Tripathy, Debasish, Ueno, Naoto T, Valero, Vicente   +12 more
core   +2 more sources

Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy

Breast Cancer Research, 2023
Background Most patients with estrogen receptor positive (ER+) breast cancer do not respond to immune checkpoint inhibition (ICI); the tumor microenvironment (TME) of these cancers is generally immunosuppressive and contains few tumor-infiltrating ...
Kathleen A. O’Leary, Amber M. Bates, Won Jong Jin, Brian M. Burkel, Raghava N. Sriramaneni, Sarah E. Emma, Erin J. Nystuen, Elizabeth G. Sumiec, Suzanne M. Ponik, Zachary S. Morris, Linda A. Schuler   +10 more
doaj   +1 more source

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer [PDF]

, 2018
Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing ...
A Carracedo, A Subramanian, AH Evans, Allan Thornhill, Alshad S. Lalani, Aradhana Rani, C Trapnell, CK Osborne, CX Ma, Eugene Schuster, FL Chen, Francesca Avogadri-Connors, G Arpino, HJ Burstein, IE Smith, J Baselga, Joanna Nikitorowicz-Buniak, KE Bachman, KE O'Reilly, L Gandhi, LA Martin, LA Martin, Lesley-Ann Martin, LV Sequist, M Arnedos, M Dowsett, Mitch Dowsett, MT Weigel, N Patani, N Simigdala, NA O'Brien, Nikiana Simigdala, R Ribas, Ricardo Ribas, Richard E. Cutler, S Johnston, SC Drury, SN Mohd Nafi, SP Newman, Stephanie K. Guest, Stephen R. Johnston, Sunil Pancholi, T Nagashima, W Luo   +43 more
core   +6 more sources

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Fulvestrant-induced toxic epidermal necrolysis [PDF]

Anais Brasileiros de Dermatologia, 2019
Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast ...
Macarena Morales-Conde, Natividad López-Ibáñez, Julio Calvete-Candenas, Francisco Manuel Ildefonso Mendonça   +3 more
doaj   +1 more source

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice

Медицинский совет, 2021
Introduction. Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast cancer (ABC) after progression on hormonotherapy.
D. A. Filonenko, T. M. Ibragimova, N. I. Polshina, A. V. Belogurova, E. I. Khatkova, E. A. Arutiunian, E. I. Volkova, L. G. Zhukova   +7 more
doaj   +1 more source

Current medical treatment of estrogen receptor-positive breast cancer [PDF]

, 2015
Approximately 80% of breast cancers (BC) are estrogen receptor (ER)-positive and thus endocrine therapy (ET) should be considered complementary to surgery in the majority of patients.
Basso, S. M. M., Lumachi, Franco, Santeufemia, D. A.   +2 more
core   +1 more source

Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]

, 2018
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G., Cognetti, F., Fabi, A., Gasparro, S., Malaguti, P., Vidiri, A.   +5 more
core   +1 more source